Originally published as JCO Early Release 10.1200/JCO.2006.06.5664 on November 20 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haffty, B. G. Articles by Toppmeyer, D. Search for Related Content PubMed PubMed Citation Articles by Haffty, B. G. Articles by Toppmeyer, D. Related Articles Related Correspondence Social Bookmarking                            What's this?

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

Bruce G. Haffty, Qifeng Yang, Michael Reiss, Thomas Kearney, Susan A. Higgins, Joanne Weidhaas, Lyndsay Harris, Willam Hait, Deborah Toppmeyer

From the Departments of Radiation Oncology, Medical Oncology, and Surgery, Cancer Institute of New Jersey, Robert Wood Johnson Medical School–University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; and Department of Therapeutic Radiology and Section of Medical Oncology, Yale University School of Medicine, New Haven, CT

Address reprint requests to Bruce G. Haffty, MD, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany St, New Brunswick, NJ 08903-2681; e-mail: hafftybg{at}umdnj.edu

PURPOSE: To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients.

PATIENTS AND METHODS: A database of conservative managed (conservative surgery followed by radiation) patients, in whom all three markers (estrogen receptor, progesterone receptor, and HER2/neu) were available, was reviewed. Patients were classified as triple negative if they tested negative for all three markers. Of 482 patients with all three markers available, 117 were classified as triple negative.

RESULTS: As of September 2005, with a median follow-up time of 7.9 years, of the 482 patients in the study, there have been 53 in-breast relapses, 10 nodal relapses, 77 distant relapses, and 69 deaths. At 5 years, the triple negative cohort had a poorer distant metastasis-free rate compared with the other subtypes (67% v 82%, respectively; P = .002). Triple negative subtype was an independent predictor of distant metastasis (hazard ratio = 2.14; 95% CI, 1.31 to 3.53; P = .002) and cause-specific survival (hazard ratio = 1.79; 95% CI, 1.03 to 3.22; P = .047). There was no significant difference in local control between the triple negative and other subtypes (83% v 83%, respectively). Of 99 BRCA-tested patients in this cohort, 10 had deleterious mutations in BRCA1, and seven had mutations in BRCA2. Of 10 BRCA1 patients, eight were triple negative, whereas only one of seven BRCA2 patients was triple negative (P < .001).

CONCLUSION: Patients classified as triple negative have a poor prognosis. However, there was no evidence that these patients are at higher risk for local relapse after conservative surgery and radiation. Patients with BRCA1 mutations develop predominantly triple negative tumors.

published online ahead of print at www.jco.org on November 20, 2006.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Potential Chemotherapy Options in the Triple Negative Subtype of Breast Cancer
  Kadri Altundag, Hakan Harputluoglu, Sercan Aksoy, and Ibrahim H. Gullu
  JCO 2007 25: 1294-1295 [Full Text]

This article has been cited by other articles:

				A. W. Kurian, L. A. McClure, E. M. John, P. L. Horn-Ross, J. M. Ford, and C. A. Clarke Second Primary Breast Cancer Occurrence According to Hormone Receptor Status J Natl Cancer Inst, July 9, 2009; (2009) djp181v1. [Abstract] [Full Text] [PDF]

				S Pintens, P Neven, M Drijkoningen, V Van Belle, P Moerman, M-R Christiaens, A Smeets, H Wildiers, and I V. Bempt Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1 J. Clin. Pathol., July 1, 2009; 62(7): 624 - 628. [Abstract] [Full Text] [PDF]

				J. S. Koo, W. Jung, and J. Jeong The Predictive Role of E-cadherin and Androgen Receptor on In Vitro Chemosensitivity in Triple-negative Breast Cancer Jpn. J. Clin. Oncol., June 16, 2009; (2009) hyp065v1. [Abstract] [Full Text] [PDF]

				B. G. Haffty, D. H. Choi, S. Goyal, A. Silber, K. Ranieri, E. Matloff, M. H. Lee, M. Nissenblatt, D. Toppmeyer, and M. S. Moran Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups Ann. Onc., June 2, 2009; (2009) mdp051v1. [Abstract] [Full Text] [PDF]

				A. Moreno-Aspitia and E. A. Perez Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545. [Abstract] [Full Text] [PDF]

				E. Alli, V. B. Sharma, P. Sunderesakumar, and J. M. Ford Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase Cancer Res., April 15, 2009; 69(8): 3589 - 3596. [Abstract] [Full Text] [PDF]

				B. J. Chae, J. S. Bae, A. Lee, W. C. Park, Y. J. Seo, B. J. Song, J. S. Kim, and S. S. Jung p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer Jpn. J. Clin. Oncol., April 1, 2009; 39(4): 217 - 224. [Abstract] [Full Text] [PDF]

				J. M. Dolle, J. R. Daling, E. White, L. A. Brinton, D. R. Doody, P. L. Porter, and K. E. Malone Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1157 - 1166. [Abstract] [Full Text] [PDF]

				A. Spitale, P. Mazzola, D. Soldini, L. Mazzucchelli, and A. Bordoni Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland Ann. Onc., April 1, 2009; 20(4): 628 - 635. [Abstract] [Full Text] [PDF]

				S. Dawood, K. Broglio, F. J. Esteva, W. Yang, S.-W. Kau, R. Islam, C. Albarracin, T. K. Yu, M. Green, G. N. Hortobagyi, et al. Survival among women with triple receptor-negative breast cancer and brain metastases Ann. Onc., April 1, 2009; 20(4): 621 - 627. [Abstract] [Full Text] [PDF]

				T. Uematsu, M. Kasami, and S. Yuen Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings Radiology, March 1, 2009; 250(3): 638 - 647. [Abstract] [Full Text] [PDF]

				D. Gao, J. Du, L. Cong, and Q. Liu Risk Factors for Initial Lung Metastasis from Breast Invasive Ductal Carcinoma in Stages I-III of Operable Patients Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 97 - 104. [Abstract] [Full Text] [PDF]

				T. A. Buchholz Radiation Therapy for Early-Stage Breast Cancer after Breast-Conserving Surgery N. Engl. J. Med., January 1, 2009; 360(1): 63 - 70. [Full Text] [PDF]

				L. Vona-Davis, D. P. Rose, H. Hazard, M. Howard-McNatt, F. Adkins, J. Partin, and G. Hobbs Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3319 - 3324. [Abstract] [Full Text] [PDF]

				A. D. Spearman, K. Sweet, X.-P. Zhou, J. McLennan, F. J. Couch, and A. E. Toland Clinically Applicable Models to Characterize BRCA1 and BRCA2 Variants of Uncertain Significance J. Clin. Oncol., November 20, 2008; 26(33): 5393 - 5400. [Abstract] [Full Text] [PDF]

				M. Schmidt, D. Hasenclever, M. Schaeffer, D. Boehm, C. Cotarelo, E. Steiner, A. Lebrecht, W. Siggelkow, W. Weikel, I. Schiffer-Petry, et al. Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer Clin. Cancer Res., September 15, 2008; 14(18): 5849 - 5855. [Abstract] [Full Text] [PDF]

				D. P. Atchley, C. T. Albarracin, A. Lopez, V. Valero, C. I. Amos, A. M. Gonzalez-Angulo, G. N. Hortobagyi, and B. K. Arun Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer J. Clin. Oncol., September 10, 2008; 26(26): 4282 - 4288. [Abstract] [Full Text] [PDF]

				S. L. Hines, L. A. Vallow, W. W. Tan, R. B. McNeil, E. A. Perez, and A. Jain Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer Ann. Onc., September 1, 2008; 19(9): 1561 - 1565. [Abstract] [Full Text] [PDF]

				E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis Basal-Like Breast Cancer: A Critical Review J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581. [Abstract] [Full Text] [PDF]

				P. L. Nguyen, A. G. Taghian, M. S. Katz, A. Niemierko, R. F. Abi Raad, W. L. Boon, J. R. Bellon, J. S. Wong, B. L. Smith, and J. R. Harris Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy J. Clin. Oncol., May 10, 2008; 26(14): 2373 - 2378. [Abstract] [Full Text] [PDF]

				E Korsching, S S Jeffrey, W Meinerz, T Decker, W Boecker, and H Buerger Basal carcinoma of the breast revisited: an old entity with new interpretations J. Clin. Pathol., May 1, 2008; 61(5): 553 - 560. [Abstract] [Full Text] [PDF]

				Y. Eralp, D. Derin, Y. Ozluk, E. Yavuz, N. Guney, P. Saip, M. Muslumanoglu, A. Igci, S. Kucucuk, M. Dincer, et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer Ann. Onc., April 1, 2008; 19(4): 669 - 674. [Abstract] [Full Text] [PDF]

				M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426. [Abstract] [Full Text] [PDF]

				C. Liedtke, C. Mazouni, K. R. Hess, F. Andre, A. Tordai, J. A. Mejia, W. F. Symmans, A. M. Gonzalez-Angulo, B. Hennessy, M. Green, et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer J. Clin. Oncol., March 10, 2008; 26(8): 1275 - 1281. [Abstract] [Full Text] [PDF]

				M. C.U. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. K. Chia, C. M. Perou, and T. O. Nielsen Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype Clin. Cancer Res., March 1, 2008; 14(5): 1368 - 1376. [Abstract] [Full Text] [PDF]

				E. J. Wasserman and A. R. Tan Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126. [Abstract] [Full Text] [PDF]

				J.-H. Chen, R. S. Mehta, P. M. Carpenter, O. Nalcioglu, and M.-Y. Su Magnetic Resonance Imaging in Predicting Pathological Response of Triple Negative Breast Cancer Following Neoadjuvant Chemotherapy J. Clin. Oncol., December 10, 2007; 25(35): 5667 - 5669. [Full Text] [PDF]

				J.-H. Chen, G. Agrawal, B. Feig, H.-M. Baek, P. M. Carpenter, R. S. Mehta, O. Nalcioglu, and M.-Y. Su Triple-negative breast cancer: MRI features in 29 patients Ann. Onc., December 1, 2007; 18(12): 2042 - 2043. [Full Text] [PDF]

				E. S. Thomas, H. L. Gomez, R. K. Li, H.-C. Chung, L. E. Fein, V. F. Chan, J. Jassem, X. B. Pivot, J. V. Klimovsky, F. H. de Mendoza, et al. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment J. Clin. Oncol., November 20, 2007; 25(33): 5210 - 5217. [Abstract] [Full Text] [PDF]

				C. U. Ihemelandu, L. D. Leffall Jr., R. L. Dewitty, T. J. Naab, H. M. Mezghebe, K. H. Makambi, L. Adams-Campbell, and W. A. Frederick Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome Ann. Surg. Oncol., October 1, 2007; 14(10): 2994 - 3003. [Abstract] [Full Text] [PDF]

				L. Harris, D. Toppmeyer, and B. G. Haffty In Reply J. Clin. Oncol., April 1, 2007; 25(10): 1295 - 1296. [Full Text] [PDF]

				K. Altundag, H. Harputluoglu, S. Aksoy, and I. H. Gullu Potential Chemotherapy Options in the Triple Negative Subtype of Breast Cancer J. Clin. Oncol., April 1, 2007; 25(10): 1294 - 1295. [Full Text] [PDF]